© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
63 Luarca st.
Vista Verde Exec Vill
March 12, 2021
Pal detailed the plan for the CONTACT-03 study and what the research team hopes to see with the data.
March 10, 2021
Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.
March 08, 2021
Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.
February 12, 2021
Pal discussed findings from the SWOG 1500 trial investigating sunitinib versus either cabozantinib, crizotinib, or savolitinib to treat patients with metastatic papillary RCC.
February 19, 2017
This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.
June 15, 2015
Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.
July 15, 2014
Adrenocortical carcinoma is a rare disease, with an annual incidence rate ranging from 0.5 to 2.0 cases per million individuals.